Select Page
Hoth Therapeutics: Orphan Drug Designation for HT-KIT

Hoth Therapeutics: Orphan Drug Designation for HT-KIT

Hoth Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to HT-KIT to treat mastocytosis. Mastocytosis is a rare condition caused by an abnormal accumulation and activation of mast cells in the skin, bone...
C4 Therapeutics: Orphan Drug Designation for CFT8634

C4 Therapeutics: Orphan Drug Designation for CFT8634

C4 Therapeutics (C4T) has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 to treat soft tissue sarcoma. Soft tissue sarcoma is a rare type of cancer that begins in the tissues that connect, support, and...
Genmab: Orphan Drug Designation for Epcoritamab

Genmab: Orphan Drug Designation for Epcoritamab

Genmab A/S has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine epcoritamab (DuoBody®-CD3xCD20) to treat follicular lymphoma (FL). FL is usually a slow-growing or indolent form of...